Novartis’ Cell-based Vaccine: Seasonal Approval With Pandemic Implications
This article was originally published in The Pink Sheet Daily
Executive Summary
The Flucelvax flu vaccine is the first approved in the U.S. that is derived from cell-based technology instead of the traditional egg-based process. It will be made at Novartis’ Holly Springs, N.C. plant.